Munger Mode rating: 4 out of 5 — Buy. Our own rating from the research report below, on business quality first: moat durability and management, with price separating the top three.
Written in the voice of Warren Buffett and Charlie Munger, based on the Q2 2026 10-Q (period ended June 30, 2026), the July 23 earnings release, and current market data. We spend most of our lives looking for businesses where the customer cannot leave, the product is a sliver of the customer's total cost, and every unit the end market consumes must be bought again. West Pharmaceutical Services is one of the purest examples of that combination we know of in the S&P 500. It makes the rubber stoppers, plungers, and seals that sit inside virtually every injectable drug on earth — roughly 70% of injectable medicines sold use a West or Daikyo component — and once a component is written into a drug's regulatory filing, replacing it requires stability studies and regulatory amendments no sane pharmaceutical company undertakes to save a fraction of a penny per dose.
Recent filings analysed: 8-K (2026-07-23), 10-Q (2026-07-23), 8-K (2026-07-14), 8-K (2026-06-01).
Stock screener · Superinvestor 13F holdings · Analyst sentiment · Market valuation